Search results
Prince William's Inner 'H—': Future King 'Suffered His Own Private Turmoil' During Kate Middleton...
OK! Magazine· 3 days agoPrince William, heir to the British throne, went through the wringer earlier this year when both his...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 4 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 7 days ago"Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials" was originally...
FDA grants Shattuck Labs orphan drug status for AML treatment By Investing.com
Investing.com· 15 hours agoThis status is expected to bolster the drug's development through various incentives, including...
Ex-GOP Comms Director Unleashes Her Truth About 'MAGA World' After Verdict Hoax
HuffPost via Yahoo News· 19 hours ago@TaraSetmayer on the GOP relying on a debunked conspiracy theory from a Facebook troll to demand a...
GENMAB A/S/S (OTCMKTS:GMXAY) and LianBio (NASDAQ:LIAN) Critical Contrast
ETF DAILY NEWS· 7 hours agoLianBio (NASDAQ:LIAN – Get Free Report) and GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses ...
BeiGene, Ltd. (NASDAQ:BGNE) Receives $251.93 Average PT from Brokerages
ETF DAILY NEWS· 6 hours agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. Two research analysts have ...
Get Full Control Of Your T Cell Isolation For Your CAR T Cell Therapy Manufacturing
BioresearchOnline· 7 days agoCell therapies offer promising avenues for potentially treating malignancies that are currently...
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological...
Benzinga· 4 days agoHONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin
Newswise Expert | Afshin Dowlati, Case Western Reserve University
Newswise· 4 days agoMy research is focused on the translational aspects of target validation and drug development and I am uniquely positioned to perform preclinical studies of novel drugs in cancer models with ...